Immunotherapy and allogeneic stem cells transplantation

被引：0

作者：

de Fontbrune, Flore Sicre ^{[1
]}

Cavalieri, Doriane ^{[2
]}

Leclerc, Mathieu ^{[3
]}

Beckerich, Florence ^{[3
]}

Maury, Sebastien ^{[3
]}

de latour, Regis Peffault ^{[1
]}

N-Guyen, Stephanie ^{[4
]}

Bay, Jacques-Olivier ^{[2
]}

机构：

[1] GH Henri Mondor, Hematol Clin & Transplantat, Creteil, France

[2] CHU Clermont Ferrand, Serv Theapie Cellulaire & Hematol Clin Adulte, Site Estaing 1,Pl Lucie Aubrac, F-63000 Clermont Ferrand, France

[3] Hop St Louis, Serv Hematol Greffe Moelle, 1 Ave Claude Vellefaux, F-75475 Paris 10, France

[4] Univ Paris 06, Univ Sorbonne, AP HP,CNRS ERL8255,Serv Hematol Clin, Ctr Immunol & Malad Infect CIMI Paris,INSERM U113, Paris, France

来源：

BULLETIN DU CANCER | 2016年 / 103卷

关键词：

HLA typing; Allogeneic transplantation; Immunotherapy; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; DONOR LYMPHOCYTE INFUSIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; CORD BLOOD TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; MINOR HISTOCOMPATIBILITY ANTIGENS; DE-THERAPIE-CELLULAIRE; REDUCED-INTENSITY; T-CELLS;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Allogeneic stem cell transplantations represent perfect example of immunotherapy. Its positive aspects are due to the graft versus tumor effect. Unfortunately, this therapeutic advantage is usually associated with graft versus host effects. While the mechanism of these two graft reactions remain unclear, this is possible to modulate these immunologic effects. The type of conditioning regimen, the source of donor and the use of donor cells after the transplantation may influence the toxicity and the tumor response, leading to a better optimization of the procedure. This paper is presenting all the parameters which may contribute to improve allogeneic stem cell transplantations.

引用

页码：S164 / S174

页数：11

共 50 条

[21] Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies
Kolb, HJ
Simoes, B
Schmid, C
CURRENT OPINION IN ONCOLOGY, 2004, 16 (02) : 167 - 173
[22] Immunotherapy with allogeneic haematopoietic stem cell transplantation: current status and perspectives
Mohty, M
Faucher, C
Blaise, D
REVUE DE MEDECINE INTERNE, 2005, 26 (01): : 33 - 40
[23] Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs
Festuccia, Moreno
Martino, Massimo
Ferrando, Federica
Messina, Giuseppe
Moscato, Tiziana
Fedele, Roberta
Boccadoro, Mario
Giaccone, Luisa
Bruno, Benedetto
EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (06) : 857 - 872
[24] Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation
Cieri, Nicoletta
Mastaglio, Sara
Oliveira, Giacomo
Casucci, Monica
Bondanza, Attilio
Bonini, Chiara
IMMUNOLOGICAL REVIEWS, 2014, 257 (01) : 165 - 180
[25] Adoptive immunotherapy ± Ruxolitinib and second allogeneic hematopoietic stem cell transplantation in patients with relapsed Myelofibrosis after allogeneic hematopoietic stem cell transplantation
Bogdanov, R.
Ditschkowski, M.
Steckel, N. -K.
Klisanin, V.
Kordelas, L.
Trenschel, R.
Beelen, D. W.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 60 - 61
[26] Allogeneic transplantation as anticancer immunotherapy
Parmar, Simrit
Ritchie, David S.
CURRENT OPINION IN IMMUNOLOGY, 2014, 27 : 38 - 45
[27] Conditioning with treosulfan in allogeneic transplantation of hemopoietic stem cells
Zecca, M.
Giorgiani, G.
Bonetti, F.
Calafiore, L.
Cugno, C.
Decembrino, N.
Gagliardone, C.
Mina, T.
Rubert, L.
Zavras, N.
Comoli, P.
PEDIATRIC REPORTS, 2012, 4 : 41 - 43
[28] Allogeneic transplantation of blood stem cells: Coming of age?
Dreger, P
Schmitz, N
ANNALS OF HEMATOLOGY, 2001, 80 (03) : 127 - 136
[29] Regulatory T Cells in Allogeneic Stem Cell Transplantation
Michael, Maria
Shimoni, Avichai
Nagler, Arnon
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2013,
[30] Allogeneic transplantation using peripheral blood stem cells
Russell, NH
Byrne, JL
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2001, 14 (04) : 685 - 700

← 1 2 3 4 5 →